Contrast Media Sales

Contrast Media Sales Market Outlook

The global contrast media market is anticipated to reach approximately USD 6.4 billion by 2035, growing at a compound annual growth rate (CAGR) of 6.2% from 2025 to 2035. This growth can be attributed to the rising prevalence of chronic diseases, an increase in diagnostic imaging procedures, and advancements in contrast media technology. Additionally, the ongoing demand for minimally invasive procedures in interventional radiology is further propelling the market forward. The increasing investments in healthcare infrastructure, particularly in developing regions, and the rising awareness among healthcare professionals regarding the benefits of contrast agents are expected to significantly contribute to the market expansion. Furthermore, the growing aging population requiring frequent imaging diagnostics will also play a crucial role in this growth trajectory.

Growth Factor of the Market

The contrast media market is primarily driven by the growing demand for advanced imaging techniques. As more healthcare facilities adopt modern diagnostic technologies, the utilization of contrast media in imaging procedures becomes increasingly prevalent. Additionally, the rise in the number of procedures such as MRI, CT, and ultrasound scans, necessitating the use of contrast agents for enhanced visibility and accuracy, further fuels market growth. Innovations in formulation and delivery methods have improved the safety profiles of these agents, reducing the risks associated with allergic reactions and enhancing patient comfort. Furthermore, the expansion of healthcare access in emerging markets fosters a higher volume of diagnostic imaging, creating new opportunities for market participants. Collaborations between healthcare providers and technology developers are also playing a significant role in shaping the market, as they aim to introduce more effective and efficient contrast media solutions.

Key Highlights of the Market

• The global contrast media market is projected to reach USD 6.4 billion by 2035, with a CAGR of 6.2%.
• Increased prevalence of chronic diseases is leading to a higher demand for diagnostic imaging.
• Technological advancements in contrast media formulations are enhancing safety and efficacy.
• Emerging markets are witnessing significant growth opportunities due to expanding healthcare access.
• Collaboration between healthcare providers and tech firms is driving innovation in the market.

By Product Type

Iodinated Contrast Media:

Iodinated contrast media are the most widely used agents in imaging procedures, particularly in computed tomography (CT) scans and angiography. These agents contain iodine, which effectively absorbs X-rays, enhancing the contrast of blood vessels and organs in imaging studies. The increasing incidence of cardiovascular diseases and the corresponding rise in interventional radiology procedures are key factors driving demand for iodinated contrast media. Furthermore, ongoing research is aimed at reducing the adverse effects associated with these agents, contributing to their broad acceptance in clinical practice. The development of non-ionic iodinated contrast agents has also improved safety profiles, making them preferable for patients with allergies or renal issues.

Gadolinium-based Contrast Media:

Gadolinium-based contrast agents are primarily utilized in magnetic resonance imaging (MRI) due to their unique properties that enhance image clarity without exposing patients to ionizing radiation. The growth of the MRI market, fueled by its increasing application in neurological, oncological, and musculoskeletal imaging, significantly contributes to the demand for gadolinium-based contrast media. Additionally, the development of new formulations that minimize the risk of nephrogenic systemic fibrosis (NSF) is enhancing the appeal of these agents. The focus on expanding the applications of gadolinium-based media in functional imaging and other innovative techniques is expected to drive further growth in this segment.

Barium-based Contrast Media:

Barium-based contrast media are primarily used in gastrointestinal tract imaging, particularly in fluoroscopy and CT studies. These agents offer excellent visualization of the gastrointestinal system, assisting in the diagnosis of conditions such as tumors, ulcers, and inflammatory diseases. The ongoing advancements in barium formulations, including the development of low-density barium suspensions for improved patient comfort and reduced side effects, are expected to sustain growth in this market segment. Furthermore, the rising incidence of gastrointestinal disorders and the increasing demand for outpatient imaging services are likely to enhance the adoption of barium-based contrast media.

Microbubble Contrast Media:

Microbubble contrast media are gaining traction in ultrasound imaging, particularly in echocardiography and vascular imaging applications. These agents consist of tiny gas-filled bubbles that provide enhanced echogenicity, allowing for improved visualization of blood flow and cardiac structures. The minimally invasive nature of ultrasound imaging compared to other diagnostic modalities adds to the attractiveness of microbubble contrast agents. As healthcare providers seek to expand the range of applications for ultrasound imaging, the demand for microbubble agents is expected to grow. Ongoing research into new formulations that improve the stability and circulation time of microbubbles is likely to further push the market forward.

Others:

This category encompasses various niche contrast media that do not fit into the primary classifications. These may include alternative agents such as iron oxide nanoparticles and other innovative formulations that are being explored for specialized imaging applications. While the market share for these agents is currently smaller compared to conventional contrast media, ongoing research and development efforts aim to uncover their potential benefits in specific clinical scenarios. The increasing focus on personalized medicine and the need for better-targeted imaging solutions may drive growth in this segment as new developments emerge.

By Application

Diagnostic Imaging:

Diagnostic imaging represents the largest application segment for contrast media, driven by the growing number of imaging procedures performed globally. Technologies such as CT, MRI, and ultrasound require the use of contrast agents to enhance the visibility of anatomical structures and pathologies. The rise in preventive healthcare and routine screenings for early disease detection further bolsters the demand for diagnostic imaging. Additionally, advancements in imaging technologies, such as 3D and functional imaging, necessitate the use of highly effective contrast media for accurate diagnoses. The transition towards digital healthcare and telemedicine is also expected to increase the utilization of diagnostic imaging, thus contributing to market growth.

Radiology:

Radiology is a specialized field that heavily relies on contrast media to improve the diagnosis of various conditions through imaging techniques. The increasing number of radiological examinations performed in hospitals and clinics, driven by the rise in chronic diseases and the aging population, has led to a growing demand for contrast agents. Radiologists require high-quality imaging for accurate assessments, and the use of contrast media significantly enhances the diagnostic capabilities of radiological procedures. Furthermore, the integration of artificial intelligence in radiology is expected to propel the demand for sophisticated imaging solutions, including advanced contrast media, to assist in interpreting complex data.

Interventional Radiology:

Interventional radiology is an emerging area that utilizes imaging techniques to guide minimally invasive surgical procedures. The use of contrast media is critical in this field, as it provides real-time visualization of structures during interventions, enhancing procedural safety and effectiveness. The increasing acceptance of interventional radiology for various therapeutic applications, such as tumor ablation and vascular interventions, is expected to drive the growth of contrast agents in this segment. Additionally, ongoing innovations in interventional techniques and equipment are likely to expand the scope of procedures performed, further increasing the reliance on effective contrast media.

Others:

This category includes applications of contrast media in various specialized fields outside the primary imaging areas. These may encompass emerging applications in research settings, veterinary medicine, and experimental imaging techniques. As the medical field continues to evolve, new applications for contrast media are being explored, driven by the need for enhanced imaging solutions in niche markets. The ongoing collaboration between academic institutions and industry players is likely to unveil additional uses and formulations for contrast agents, potentially expanding this segment's market presence.

By Distribution Channel

Hospitals:

Hospitals are the primary distribution channel for contrast media, accounting for a significant portion of the market share. The demand for contrast agents in hospitals is driven by the increasing number of imaging procedures performed daily, particularly in emergency departments and outpatient settings. Hospitals often possess advanced imaging equipment, which enables them to utilize a wide range of contrast media effectively. Additionally, the consolidation of healthcare facilities and the establishment of integrated care systems are likely to enhance the procurement and usage of contrast media in hospitals. As the focus on improving patient outcomes and operational efficiency continues, hospitals will remain a vital channel for contrast media distribution.

Diagnostic Imaging Centers:

Diagnostic imaging centers play a crucial role in the distribution of contrast media, particularly as outpatient services gain prominence. These centers specialize in various imaging modalities and often cater to a diverse patient population seeking diagnostic evaluations. The convenience and accessibility of imaging centers, combined with the rising demand for preventive healthcare, have led to increased utilization of contrast agents in these settings. As imaging technology continues to advance, diagnostic imaging centers are likely to expand their services and invest in high-quality contrast media to enhance diagnostic accuracy. The growth of these centers is an essential factor contributing to the overall expansion of the contrast media market.

Ambulatory Surgical Centers:

Ambulatory surgical centers (ASCs) are increasingly incorporating imaging services, including those requiring contrast media, into their offerings. These centers provide same-day surgical procedures and often utilize imaging technology for preoperative planning and postoperative assessments. The growing trend toward outpatient care and the need for cost-effective solutions are driving the demand for contrast agents in ASCs. As surgical modalities evolve and more procedures become outpatient-based, the reliance on imaging techniques that utilize contrast media will likely increase, contributing to the segment's growth. The focus on patient satisfaction and quality of care in ASCs further emphasizes the importance of using effective contrast agents in surgical applications.

Others:

This segment includes various distribution channels that are not encompassed by hospitals, diagnostic imaging centers, or ambulatory surgical centers. It may involve distribution through pharmacies, online platforms, and other specialized healthcare providers. The increasing trend of e-commerce in healthcare is facilitating the availability of contrast media beyond traditional distribution channels. As patients and healthcare providers seek more convenient purchasing options, this segment is expected to see gradual growth. The ongoing evolution of distribution strategies in the healthcare sector, driven by technological advancements, will likely shape the future landscape of contrast media availability.

By Ingredient Type

Iodine:

Iodine-based contrast media are the predominant type used in medical imaging. These agents are known for their excellent X-ray attenuation properties, making them ideal for procedures such as CT scans and angiography. The increasing incidence of cardiovascular diseases and the corresponding rise in the number of imaging procedures utilizing iodine-based agents are key drivers of this segment. Moreover, ongoing advancements in iodinated contrast media formulations, such as the development of non-ionic agents that reduce the risk of adverse reactions, are expected to sustain growth in this category. As the healthcare industry continues to prioritize patient safety, the use of iodine-based contrast media will remain a mainstay in diagnostic imaging.

Gadolinium:

Gadolinium-based contrast agents are primarily used in MRI due to their unique properties that enhance image quality without exposing patients to radiation. The increasing demand for MRI scans in various medical fields, including oncology and neurology, significantly contributes to the growth of gadolinium-based contrast media. Innovations aimed at reducing the potential risks associated with gadolinium, such as nephrogenic systemic fibrosis (NSF), have also enhanced the appeal of these agents among healthcare professionals. As the applications of MRI continue to expand, the demand for gadolinium-based contrast agents is expected to rise, driven by the need for enhanced diagnostic precision.

Barium:

Barium contrast media are predominantly used in gastrointestinal imaging, providing excellent visualization of the digestive tract during fluoroscopy and CT scans. The rising incidence of gastrointestinal disorders, such as Crohn's disease and colorectal cancer, is driving the demand for barium-based agents. Additionally, advancements in barium formulations, including products that minimize patient discomfort, are enhancing the adoption of these agents in clinical practice. As healthcare providers increasingly recognize the importance of early diagnosis in managing gastrointestinal conditions, the market for barium contrast media is expected to grow steadily.

Others:

This segment includes various alternative ingredient types used in specialized applications, such as iron oxide nanoparticles and other innovative formulations. While these alternatives currently represent a smaller market share compared to iodine, gadolinium, and barium, ongoing research and development are revealing their potential benefits in niche imaging applications. The increased focus on personalized medicine and targeted therapies may drive interest in these alternative agents as healthcare providers seek tailored diagnostic solutions. As the landscape of medical imaging continues to evolve, the exploration of new ingredient types will likely expand this segment's offerings and market presence.

By Region

The North American region dominates the contrast media market, accounting for approximately 40% of the total market share. This dominance can be attributed to the high prevalence of chronic diseases, the presence of advanced healthcare infrastructure, and the widespread adoption of cutting-edge imaging technologies. The U.S. is particularly significant in driving market growth due to its large population base and the substantial investments made in healthcare research and development. The CAGR for the North American market is expected to remain strong, driven by the ongoing advancements in contrast media formulations and the increasing number of imaging procedures performed across various healthcare settings.

Europe follows closely as the second-largest market for contrast media, representing around 30% of the global share. The region benefits from well-established healthcare systems and a high level of awareness regarding the importance of diagnostic imaging in disease management. The aging population in Europe, coupled with the rising incidence of chronic diseases, is expected to contribute to an increased demand for contrast agents in the coming years. Furthermore, the regulatory environment in Europe is increasingly supportive of innovative contrast media developments, which will likely foster growth in the market. The Asia Pacific region is also emerging as a significant market, with a projected CAGR of 7.5%, driven by rising healthcare expenditures and an increasing focus on preventive healthcare.

Opportunities

The contrast media market presents a multitude of opportunities, particularly in emerging markets where healthcare access is rapidly expanding. As countries in the Asia Pacific and Latin America regions continue to invest in healthcare infrastructure, there is a growing demand for advanced diagnostic imaging technologies, including contrast media. The increasing prevalence of lifestyle-related diseases necessitates early detection and effective management strategies, thereby driving the use of contrast agents. Moreover, the introduction of innovative and safer formulations of contrast media designed to minimize adverse reactions opens new avenues for market penetration. Companies that focus on developing products tailored to the specific needs of diverse patient populations will likely gain a competitive edge in these regions.

Another significant opportunity lies within the realm of technological advancements and innovations in imaging methods. The integration of artificial intelligence and machine learning in imaging procedures is transforming the landscape of diagnostics, leading to more precise and faster interpretations of imaging studies. As healthcare providers seek to improve patient outcomes and streamline processes, the demand for contrast media that can enhance these advanced imaging modalities will rise. Collaborations between imaging equipment manufacturers and contrast media producers to develop comprehensive imaging solutions are expected to present lucrative opportunities for growth. Companies willing to invest in research and development to provide cutting-edge contrast media products are likely to capitalize on these emerging trends in the market.

Threats

Despite the promising growth outlook, the contrast media market also faces several threats that could impact its development. One of the primary concerns is the potential for adverse reactions associated with contrast agents, particularly iodinated and gadolinium-based media. Reports of allergic reactions and nephrotoxicity can lead to challenges in patient safety and may deter healthcare providers from utilizing these agents in certain populations. Furthermore, the increasing awareness of these risks may lead to a cautious approach in prescribing contrast media, particularly among patients with a history of allergies or renal impairment. Regulatory scrutiny surrounding the approval and use of contrast media could also pose challenges, as companies must navigate stringent guidelines to ensure safety and efficacy.

Another significant threat is the rising trend toward alternative imaging modalities that do not require the use of contrast media. Techniques such as molecular imaging and advancements in imaging technologies may reduce the reliance on traditional contrast agents in certain applications. As healthcare providers increasingly adopt these alternative approaches, the demand for conventional contrast media may face downward pressure. Additionally, competition from generic and lower-cost alternatives can erode market share and profitability for branded contrast media products. Companies must remain vigilant and adapt their strategies to stay competitive in an evolving market landscape, where innovation and patient safety are paramount.

Competitor Outlook

• GE Healthcare
• Bayer AG
• Bracco Imaging S.p.A.
• Mallinckrodt Pharmaceuticals
• Siemens Healthineers
• Fujifilm Holdings Corporation
• Canon Medical Systems Corporation
• Philips Healthcare
• Guerbet Group
• Esaote S.p.A.
• Hoffmann-La Roche Ltd.
• Agfa-Gevaert Group
• Merck KGaA
• Hitachi Medical Corporation
• Neusoft Medical Systems Co., Ltd.

The competitive landscape of the contrast media market is characterized by the presence of several key players who are actively involved in research, development, and the production of innovative contrast agents. These companies are continually striving to enhance their product offerings and expand their market share through strategic partnerships, collaborations, and mergers and acquisitions. GE Healthcare, Bayer AG, and Bracco Imaging S.p.A. are among the leading players that dominate the market, leveraging their extensive portfolios and strong distribution networks to reach a diverse range of healthcare providers. The focus on technological advancements and the pursuit of novel formulations that improve patient safety and efficacy are essential strategies employed by these companies to maintain their competitive edge.

GE Healthcare is a prominent player in the contrast media market, known for its commitment to innovation and quality. The company offers a wide range of iodinated and gadolinium-based contrast agents designed to enhance imaging capabilities across various modalities. GE Healthcare is also investing in research to develop next-generation contrast agents that minimize the risk of adverse reactions while improving diagnostic accuracy. Bayer AG is another key competitor, renowned for its strong presence in the pharmaceutical and imaging sectors. Bayer's extensive product line and focus on research and development allow it to address the evolving needs of healthcare providers and patients, ensuring their products remain at the forefront of the market.

Bracco Imaging S.p.A. is a global leader in the contrast media sector, specializing in the production of high-quality imaging agents. The company's commitment to research and development has led to the introduction of innovative contrast media solutions that cater to specific clinical requirements. Bracco's focus on enhancing patient safety and improving imaging techniques has solidified its position as a trusted provider among healthcare professionals. Other notable competitors, such as Mallinckrodt Pharmaceuticals and Siemens Healthineers, are also making significant contributions to the contrast media market by developing advanced products that align with the latest technological trends in imaging.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Bayer AG
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Merck KGaA
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Esaote S.p.A.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 GE Healthcare
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Guerbet Group
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Agfa-Gevaert Group
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Philips Healthcare
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Siemens Healthineers
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Bracco Imaging S.p.A.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Hoffmann-La Roche Ltd.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Hitachi Medical Corporation
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Mallinckrodt Pharmaceuticals
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Fujifilm Holdings Corporation
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Canon Medical Systems Corporation
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Neusoft Medical Systems Co., Ltd.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Contrast Media Sales Market, By Application
    • 6.1.1 Diagnostic Imaging
    • 6.1.2 Radiology
    • 6.1.3 Interventional Radiology
    • 6.1.4 Others
  • 6.2 Contrast Media Sales Market, By Product Type
    • 6.2.1 Iodinated Contrast Media
    • 6.2.2 Gadolinium-based Contrast Media
    • 6.2.3 Barium-based Contrast Media
    • 6.2.4 Microbubble Contrast Media
    • 6.2.5 Others
  • 6.3 Contrast Media Sales Market, By Ingredient Type
    • 6.3.1 Iodine
    • 6.3.2 Gadolinium
    • 6.3.3 Barium
    • 6.3.4 Others
  • 6.4 Contrast Media Sales Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Diagnostic Imaging Centers
    • 6.4.3 Ambulatory Surgical Centers
    • 6.4.4 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Contrast Media Sales Market by Region
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Contrast Media Sales market is categorized based on

By Product Type

• Iodinated Contrast Media
• Gadolinium-based Contrast Media
• Barium-based Contrast Media
• Microbubble Contrast Media
• Others

By Application

• Diagnostic Imaging
• Radiology
• Interventional Radiology
• Others

By Distribution Channel

• Hospitals
• Diagnostic Imaging Centers
• Ambulatory Surgical Centers
• Others

By Ingredient Type

• Iodine
• Gadolinium
• Barium
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• GE Healthcare
• Bayer AG
• Bracco Imaging S.p.A.
• Mallinckrodt Pharmaceuticals
• Siemens Healthineers
• Fujifilm Holdings Corporation
• Canon Medical Systems Corporation
• Philips Healthcare
• Guerbet Group
• Esaote S.p.A.
• Hoffmann-La Roche Ltd.
• Agfa-Gevaert Group
• Merck KGaA
• Hitachi Medical Corporation
• Neusoft Medical Systems Co., Ltd.